Weiwei Xiao

Also affiliated with Sun Yat-sen University Cancer Center, Guangdong Provincial People's Hospital, State Key Laboratory of Oncology in South China

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort”.

1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1714

N/A

0DataRank · unranked

0 citations

D. Ye, Hanxu Guo, Yuchong Yang, Bing Xue, Xiao Zhang +15 more